Visible Genomics offers advanced predictive genetic testing for macular degeneration (AMD), enabling eye care practitioners to create personalized treatment plans for their patients. Their AMDiGuard Risk and AMD iGuard Progression tests provide clinically validated assessments of a patient's risk for AMD, which can lead to earlier intervention, better outcomes, and increased patient compliance with modifiable risk factors such as diet and smoking.